Drug intelligence / Profile preview

DWJ1464

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWJ1464 is an investigational drug developed by Daewoong Pharmaceutical. It has been studied in clinical trials to evaluate its safety, pharmacokinetics, and efficacy. One clinical trial compared the pharmacokinetics and safety of DWJ1464 with other test and reference drugs in healthy adult volunteers using a randomized, open-label, oral, single-dose crossover design. Another study aims to assess the effect of DWJ1464 on improvement of liver function in patients with chronic liver disease. The precise mechanism of action for DWJ1464 has not been disclosed in publicly available sources as of April 2025.

Beyond the preview

Go deeper on DWJ1464.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1464.

Explore the full profile